Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Apr 1, 2008 → Nov 1, 2010
NCT ID
NCT00664534About Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture) is a approved stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT00664534. Target conditions include Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00664534 | Approved | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2